Highly characterized, clinically relevant models.
Fast study start-up and optimized study designs.
Primary Site | Model ID | AKA |
---|---|---|
Bladder | TM00016 | BL0293 |
Breast | TM00098 | BR1126F |
TM00089 | BR0620F | |
TM00386 | BR0555F | |
TM00096 | BR0851F | |
Colon | TM00170 | CN1572F |
Head | TM01141 | |
Lung | TM00302 | LG1306aF |
TM00219 | LG1049F | |
TM00233 | LG1202 | |
TM00193 | LG0591F | |
TM00194 | LG0627PE | |
TM00199 | LG0703F | |
Ovary | TM00335 | OV1828F |
Pancreas | TM01212 | TM01212F |
Prostate Gland | TM00298 | PR1996F |
Skin | J000106560 | PS4050 |
Additional live models may be available, and are subject to change.
For specific model availability, please contact:
Technical Information Services
micetech@jax.org
1-800-422-6423 (US, Canada & Puerto Rico)
1-207-288-5845 (from any location)
JAX Technical Support
Study Type | Arms | Vehicle | SOC | Drug A | Drug B | Combination Drug A+B |
---|---|---|---|---|---|---|
1. Pilot efficacy study | 3 | 1 | 1 | 1 | 0 | 0 |
2. Dose response | 5 | 1 | 1 | 3 | 0 | 0 |
3. Drug combination | 4 | 1 | 0 | 1 | 1 | 1 |
4. Tolerability | 3 | 1 | 0 | 2 | 0 | 0 |
We provide you data in weeks with study-ready clinically relevant patient-derived xenografts in the most robust mouse models.
Contact Technical Support
micetech@jax.org
1.800.422.6423 (US)
1.207.288.5845 (International)
Figure 1. Mice bearing passage 3 colon adenocarcinoma PDX tumor (TM00170) were treated with vehicle control: D5W (dark grey), 20mg/ kg 5-Fu (light blue), 10mg/kg Oxaliplatin (orange) and 5-Fu + Oxaliplatin (dark blue) once per week for 3 weeks. Vehicle and 5-Fu were administrated intravenously and Oxaliplatin was dosed intraperitoneally. The readout for compound efficacy–alone or in combination-was assessed by taking tumor caliper measurements and body weight twice weekly. Ten NSG™ mice were used per arm.
Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.
Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)
Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.
Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).
We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.